Home > Haematology > J&J, AbbVie cancer drug significantly slows progression of rare lymphoma -study

J&J, AbbVie cancer drug significantly slows progression of rare lymphoma -study

Reuters - 03/06/2022 - Johnson & Johnson and AbbVie's big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Friday. Patients aged 65 and older with mantle cell lymphoma (MCL) were given Imbruvica or a placebo along with a chemotherapy regimen of bendamustine and autoimmune drug rituximab. Those who received Imbruvica, known chemically as ibrutinib, on average went 80.6 months before their disease began to worsen, a measure known as progression-free survival (PFS). That compared with 52.9 months for the chemotherapy regimen in the 523-patient trial. Results of the study were presented at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago. Dr. Julie Gralow, chief medical officer of ASCO, said the study could be practice changing for doctors who t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on